Gilead to Buy Immunomedics in $21 Billion Deal for Cancer Drug

(Bloomberg) — Gilead Sciences Inc. will acquire Immunomedics Inc. for about $21 billion cash to add breast-cancer treatments, the companies said in a statement. Foster City, California-based Gilead would value Immunomedics at more than twice as much as what the maker of the Trodelvy breast-cancer drug was valued at on Friday. Pharmaceutical companies have been coveting Immunomedics since the Food and Drug Administration unexpectedly accelerated…